Montreal, CANADA – April 17th, 2019 – The Nova Scotia Health Authority (NSHA) announced today that it is working to support the commercialization of a provincially implemented software platform and assessment tools that will improve orthopaedic wait times and patient outcomes across Nova Scotia and that Emovi’s KneeKG is a key component of the solution.
The resultant product suite will address gaps in orthopaedic assessments, rehabilitative and post- operative care by providing medical staff with enhanced diagnostic information so they can make more efficient and timely clinic decisions. The NHSA collaborated/partnered with Canadian companies Kinduct Technologies Inc. , Emovi Inc., and OrthoMX , with each company having developed a key component of the product suite. The NSHA will be the first fully integrated clinical deployment.
Andy Fillmore, Parliamentary Secretary to the Minister of Canadian Heritage and Multiculturalism and Member of Parliament for Halifax, on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for the Atlantic Canada Opportunities Agency (ACOA), announced support for the NSHA project today.
Economic growth and the creation of good jobs for Atlantic Canadians require innovation and diversification. Support for this project is one way the Government of Canada is growing the innovation economy, working to sustain strategic clusters, and enhance the development and reach of business accelerators and incubators. Additionally, projects like this contribute to the Atlantic Growth Strategy outcome of long-term economic prosperity in the region.
“The research team at the Nova Scotia Health Authority has a well-earned reputation for fostering a productive research and development environment that results in innovation- based advances in healthcare. I am proud our government has chosen to support its collaborative and commercialization efforts with three Canadian companies, which will make strides to improve standards of care for orthopaedic patients across Nova Scotia.”
Andy Fillmore, Parliamentary Secretary to the Minister of Democratic Institutions and Member of Parliament for Halifax
“We are very proud to be associated to this excellent visionary project dedicated at improving care for patients. Presently, treatments for knee osteoarthritis are focusing on alleviating pain and symptoms rather than correcting biomechanical causes of disease progression and patients’ symptoms. Many physicians (46%) and patients (43%) are dissatisfied with the actual standard of care because of the lack of objective validated tools to streamline appropriate care, either through personalized conservative treatments or directed towards surgical options when appropriate, which causes a tremendous economic burden on health networks. Combining forces to streamline the process and improve the clinical efficiency and costs with Dr. Dunbar’s team at NSHA paves the way for better health for patients.”
Michelle Laflamme, Chief Executive Officer, Emovi Inc.
Emovi (Emovi.ca), headquartered in Montreal, Quebec, Canada, is a company offering medical solutions for joints assessments. In partnership with the Quebec university research community, including the CRCHUM and École de technologie supérieure (ÉTS), Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression. Emovi hopes to broaden access to this technology and improve the quality of life for people struggling with diseases such as knee osteoarthritis, ligament or meniscus tears, patellofemoral pain syndrome, tendinitis and biomechanical deficiencies resulting in pain and disability.